Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | CTSD | P07339 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573302 | 0.88 | BACE1 (0.50) | BACE1BACE2APPRENCTSD | |
| SCHEMBL3576723 | 0.83 | BACE1 (0.74) | BACE1BACE2RENCTSD | |
| SCHEMBL4109037 | 0.82 | BACE1 (0.76) | BACE1BACE2APPRENCTSD | |
| SCHEMBL3579214 | 0.82 | BACE1 (0.73) | BACE1BACE2CTSD | |
| SCHEMBL14625775 | 0.81 | BACE1 (0.46) | BACE1BACE2APPCTSD | |
| SCHEMBL4227218 | 0.80 | BACE1 (0.79) | BACE1BACE2APPRENCTSD | |
| SCHEMBL4234214 | 0.80 | BACE1 (0.79) | BACE1BACE2APPRENCTSD | |
| SCHEMBL27749223 | 0.80 | BACE1 (0.59) | BACE1BACE2APPRENCTSD | |
| SCHEMBL4228439 | 0.80 | BACE1 (0.59) | BACE1BACE2APPRENCTSD | |
| SCHEMBL4304428 | 0.79 | BACE1 (0.74) | BACE1BACE2APPRENCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168106-A1 | Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation | WYETH LLC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168106-A1 | Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation | WYETH LLC (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100168106-A1 | Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation | WYETH LLC (US) | 2010-07-01 | — | — | US | disclosed |
| US-7705030-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705030-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705030-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | WYETH (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | WYETH (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | WYETH (US) | 2008-12-11 | — | — | US | disclosed |
| US-7417047-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417047-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417047-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| CN-101213188-A | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH CORP (US) | 2008-07-02 | — | — | CN | disclosed |
| EP-1896454-A1 | AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR -SECRETASE MODULATION | Wyeth a Corporation of the State of Delaware (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005366-A1 | AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005366-A1 | AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885APP 3/4885 |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885APP 3/4885 |
| US-20100168106-A1 | Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885APP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.